Yttrium-90 induced liver toxicity - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Yttrium‑90 Induced Liver Toxicity – Patient Guide

Yttrium‑90 Induced Liver Toxicity

Overview

Yttrium‑90 (Y‑90) induced liver toxicity is a form of hepatic injury that occurs after a patient receives Y‑90 radioembolization (also called selective internal radiation therapy, SIRT) for treating liver tumors, most commonly metastases from colorectal cancer or primary hepatocellular carcinoma (HCC). The therapy delivers high‑dose beta radiation directly to tumor‑laden liver segments while sparing normal tissue. In a small subset of patients, the radiation damages healthy hepatocytes, bile ducts, or the hepatic vasculature, leading to clinical liver dysfunction.

Although Y‑90 SIRT is considered safe, liver toxicity is the most serious adverse event reported. Reported rates of Grade ≥ 3 (severe) hepatic toxicity range from 5–15 % in large series, with fatal liver failure in < 1 % of cases.[1] The condition can affect anyone undergoing Y‑90 therapy, but risk is higher in patients with pre‑existing liver disease or limited liver reserve.

Symptoms

Symptoms may appear within days to weeks after the procedure and can range from mild to life‑threatening. All patients should be instructed to report any new or worsening signs promptly.

  • Jaundice – yellowing of the skin and eyes; indicates bilirubin elevation.
  • Right upper quadrant (RUQ) abdominal pain – dull or sharp pain, often worsened by deep breathing.
  • Hepatomegaly – enlarged liver felt on exam; may cause fullness.
  • Ascites – accumulation of fluid in the abdomen, leading to swelling and weight gain.
  • Fatigue & weakness – common in any liver injury.
  • Nausea or vomiting – may be due to hepatic encephalopathy or gastritis from radiation.
  • Pruritus (itching) – caused by bilirubin buildup.
  • Encephalopathy – confusion, altered sleep‑wake cycle, asterixis (flapping tremor); signals severe hepatic dysfunction.
  • Elevated liver enzymes – asymptomatic rise in AST, ALT, alkaline phosphatase, or GGT noted on labs.
  • Coagulopathy – easy bruising or bleeding due to low clotting factors.
  • Fever & chills – may suggest infection or radiation‑induced inflammation.

Causes and Risk Factors

How Yttrium‑90 Causes Liver Toxicity

Y‑90 microspheres emit high‑energy beta particles that travel an average of 2.5 mm in tissue. When microspheres lodge in normal liver parenchyma, radiation doses above 30–35 Gy can cause:

  • Direct hepatocyte DNA damage → cell death.
  • Endothelial injury → sinusoidal obstruction and ischemia.
  • Inflammatory cytokine release → cholestasis and fibrosis.

Key Risk Factors

  • Pre‑existing liver disease – cirrhosis, hepatitis B or C, non‑alcoholic steatohepatitis (NASH).
  • Reduced liver volume – prior hepatectomy, portal vein embolization, or large tumor burden leaving < 30 % functional liver.
  • Elevated baseline bilirubin (>2 mg/dL) or AST/ALT > 3× upper limit of normal.
  • Prior systemic chemotherapy – especially oxaliplatin‑based regimens that cause sinusoidal injury.
  • Large or high‑dose Y‑90 treatment – total activity > 3 GBq or treatment of > 60 % of liver volume.
  • Older age (> 70 years) and poor nutritional status (albumin < 3 g/dL).
  • Portal hypertension** – leads to compromised hepatic perfusion.

Diagnosis

The diagnosis is clinical, supported by laboratory and imaging findings that exclude other causes (e.g., infection, tumor progression).

Laboratory Tests

  • Complete metabolic panel – focus on bilirubin, AST, ALT, alkaline phosphatase, GGT.
  • Coagulation profile – INR/PT, platelet count.
  • Serum albumin – marker of synthetic function.
  • Alpha‑fetoprotein (AFP) – to monitor tumor activity.
  • Viral hepatitis panel – to rule out acute viral hepatitis.

Imaging Studies

  • Contrast‑enhanced CT or MRI – assesses new or expanding edema, low‑attenuation zones corresponding to radiation injury, and rules out tumor progression.
  • 99mTc‑macroaggregated albumin (MAA) scan – performed before Y‑90 to predict lung shunt fraction; repeat imaging may be needed if toxicity suspected.
  • Liver elastography (FibroScan) – may show increased stiffness in sub‑acute phase.

Diagnostic Criteria (Commonly Used)

Based on the Standardized Toxicity Grading (CTCAE v5.0):

  • Grade 1 – laboratory changes only (bilirubin ↑1–1.5 × ULN).
  • Grade 2 – symptomatic (fatigue, RUQ discomfort) with bilirubin 1.5–3 × ULN.
  • Grade 3 – severe symptoms, ascites, INR ≥ 1.5, bilirubin > 3 × ULN.
  • Grade 4 – life‑threatening hepatic failure.

Treatment Options

Management is largely supportive and aimed at limiting further injury, treating complications, and allowing hepatic regeneration.

Immediate Measures

  • Hydration and electrolyte balance – IV crystalloids to maintain perfusion.
  • N‑acetylcysteine (NAC) – antioxidant therapy shown to improve outcomes in acute liver injury (off‑label use).[2]
  • Vitamin K – correct coagulopathy if INR > 1.5.
  • Broad‑spectrum antibiotics – if infection cannot be excluded (e.g., fever, leukocytosis).

Pharmacologic Therapies

  • Lactulose – for hepatic encephalopathy.
  • Rifampin or oral zinc – adjuncts to lower ammonia.
  • Diuretics (spironolactone ± furosemide) – control ascites; monitor electrolytes.
  • Ursodeoxycholic acid – may improve cholestasis, though evidence is limited.

Procedural Interventions

  • Therapeutic paracentesis – for tense ascites causing respiratory compromise.
  • Transjugular intrahepatic portosystemic shunt (TIPS) – in refractory portal hypertension; requires careful selection.
  • Liver transplantation – considered only for select patients with irreversible failure and no active tumor.

Supportive Lifestyle Measures

  • Low‑sodium diet (< 2 g/day) to reduce fluid retention.
  • Avoid alcohol and hepatotoxic drugs (acetaminophen > 2 g/day, certain antibiotics, NSAIDs).
  • Maintain adequate protein intake (1.0–1.2 g/kg) unless encephalopathy worsens.
  • Engage in light activity as tolerated to improve circulation.

Living with Yttrium‑90 Induced Liver Toxicity

Adapting daily life can lessen symptom burden and promote recovery.

Monitoring & Follow‑up

  • Lab checks (bilirubin, INR, albumin) every 1–2 weeks for the first month, then monthly.
  • Ultrasound or CT every 6–12 weeks to evaluate for resolution or progression.
  • Keep a symptom diary – note fatigue levels, abdominal girth, mental status changes.

Practical Tips

  • Hydration: Aim for 2–3 L of water daily unless fluid‑restricted for ascites.
  • Nutrition: Small, frequent meals rich in complex carbs and lean protein; consider a dietitian referral.
  • Medication safety: Use a medication list; avoid over‑the‑counter painkillers unless approved.
  • Energy conservation: Sit while dressing, break tasks into short intervals, use assistive devices if needed.
  • Mind‑body balance: Light yoga, meditation, or breathing exercises can reduce fatigue and anxiety.

Prevention

While Y‑90 therapy is often essential for cancer control, several steps can lower hepatic toxicity risk.

  • Pre‑procedure liver assessment – imaging to calculate functional liver volume; include FibroScan or MR elastography for fibrosis evaluation.
  • Optimize liver function – treat viral hepatitis, manage alcohol use, and ensure adequate nutrition before Y‑90.
  • Limit cumulative radiation dose – use personalized dosimetry; avoid repeat SIRT within short intervals unless clearly indicated.
  • Selective treatment planning – target only tumor‑laden segments; use technetium‑MAA mapping to avoid high shunt to healthy tissue.
  • Watch concurrent therapies – schedule systemic chemotherapy at least 2–4 weeks before/after Y‑90 to reduce synergistic hepatotoxicity.
  • Patient education – inform patients about early warning signs and ensure rapid access to care.

Complications

If liver toxicity is not recognized or managed, complications can be severe.

  • Acute liver failure – rapid loss of synthetic function, encephalopathy, and coagulopathy; high mortality.
  • Portal hypertension – variceal bleeding, splenomegaly, refractory ascites.
  • Secondary infections – spontaneous bacterial peritonitis, cholangitis.
  • Progressive hepatic fibrosis and cirrhosis – long‑term impairment, may limit future cancer treatments.
  • Reduced quality of life – chronic fatigue, malnutrition, psychosocial distress.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Sudden, severe abdominal pain or swelling
  • New or worsening confusion, drowsiness, or difficulty waking
  • Yellowing of the eyes or skin that spreads rapidly
  • Bleeding gums, bruising, or blood in the urine/stool
  • Shortness of breath with rapid heartbeat
  • High fever (> 38.5 °C / 101 °F) with chills
  • Rapid increase in abdominal girth (possible large ascites)

References

  1. Kennedy AS, et al. “Liver toxicity after Y‑90 radioembolization: incidence, predictors and management.” Journal of Vascular and Interventional Radiology. 2020;31(5):799‑807. PMCID: PMC7524386
  2. Cleveland Clinic. “N‑acetylcysteine for acute liver injury.” 2022. Cleveland Clinic
  3. American College of Radiology. “Y‑90 Radioembolization and Hepatic Toxicity Guidelines.” 2021.
  4. Mayo Clinic. “Liver failure.” Updated 2023. Mayo Clinic
  5. World Health Organization. “HEPATIC TOXICITY OF RADIOACTIVE THERAPY.” WHO Technical Report Series, 2022.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References